You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 2, February 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Ophthalmic Molecular Genetics
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Disorders
 •Retinal/ Chorioretinal Disorders
 •Alert me on articles by topic

Retinopathy in Danon Disease

Daniel F. Schorderet, MD; Sandra Cottet, PhD; Johannes Alexander Lobrinus, MD; François-Xavier Borruat, MD; Aubin Balmer, MD; Francis L. Munier, MD

Arch Ophthalmol. 2007;125(2):231-236.

Objective  To evaluate visual function in 2 boys and their maternal aunt affected with Danon disease due to a mutation in the X-linked lysosome-associated membrane protein-2 (LAMP2) gene.

Methods  Linkage analysis using microsatellite markers from the X chromosome was done in family members from the paternal side. Visual acuity testing, fundus analysis, fluorescence angiography, and full-field electroretinography were performed in all 3 patients.

Results  Eye examinations confirmed the presence of retinopathy in the 2 boys and their maternal aunt, obligate carrier for the S157X mutation in LAMP2. The expression of the disease was milder in the female carrier than in the hemizygous boys, possibly due to lyonization.

Conclusions  Our report further expands the phenotype of Danon disease by describing retinopathy in 3 cases. A thorough clinical examination, including ophthalmic investigation, is needed in all cases of Danon disease.

Clinical Relevance  LAMP2 belongs to a growing number of retinopathy genes. Genes involved in systemic diseases associated with poor survival may see their effect in other organs, not only in the eyes, becoming a major source of concern once a good and reliable therapy is available. This also represents a major issue for genetic counseling for patients undergoing gene therapy in the future.


Author Affiliations: IRO (Institut de Recherche en Ophtalmologie), Sion, Switzerland (Drs Schorderet and Cottet); Institut de Pathologie, Division de Neuropathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (Dr Lobrinus); and Hôpital Ophtalmique Jules-Gonin (Drs Borruat, Balmer, and Munier) and Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne (Dr Schorderet).







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.